Cite
Estimating the cost-effectiveness threshold of advanced non-small cell lung cancer in China using mean opportunity cost and contingent valuation method.
MLA
Peng, Qian, et al. “Estimating the Cost-Effectiveness Threshold of Advanced Non-Small Cell Lung Cancer in China Using Mean Opportunity Cost and Contingent Valuation Method.” Cost Effectiveness & Resource Allocation, vol. 21, no. 1, Nov. 2023, pp. 1–11. EBSCOhost, https://doi.org/10.1186/s12962-023-00487-z.
APA
Peng, Q., Yin, Y., Liang, M., Zhao, M., Shao, T., Tang, Y., Mei, Z., Li, H., & Tang, W. (2023). Estimating the cost-effectiveness threshold of advanced non-small cell lung cancer in China using mean opportunity cost and contingent valuation method. Cost Effectiveness & Resource Allocation, 21(1), 1–11. https://doi.org/10.1186/s12962-023-00487-z
Chicago
Peng, Qian, Yue Yin, Min Liang, Mingye Zhao, Taihang Shao, Yaqian Tang, Zhiqing Mei, Hao Li, and Wenxi Tang. 2023. “Estimating the Cost-Effectiveness Threshold of Advanced Non-Small Cell Lung Cancer in China Using Mean Opportunity Cost and Contingent Valuation Method.” Cost Effectiveness & Resource Allocation 21 (1): 1–11. doi:10.1186/s12962-023-00487-z.